Meningococcal vaccines: To eradicate the disease, not the bacterium

Human Vaccines

Volumn 3, Issue 4, 2007, Pages 149-152

  Taha, Muhamed Kheir ^a   Alonso, Jean Michel ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Carriage; Epidemiology; Escape; Routine vaccination; Selective vaccination; Serogroup

Indexed keywords

MENINGOCOCCUS VACCINE;

BACTERIUM ISOLATE; MENINGITIS; NEISSERIA MENINGITIDIS; REVIEW; SEPTIC SHOCK; SEPTICEMIA; VACCINATION;

EID: 34848897796     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.4.4174     Document Type: Review

References (38)

1. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: Nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987; 99:591-601.
2. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, Alvestad T, Jolley KA, Wilson DJ, McCarthy ND, Caugant DA, Maiden MC. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004; 42:5146-53.
3. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. Apmis 1998; 106:505-25.
4. Jolley KA, Kalmusova J, Feil EJ, Gupta S, Musilek M, Kriz P, Maiden MC. Carried meningococci in the Czech Republic: A diverse recombining population. J Clin Microbiol 2000; 38:4492-8.
5. Taha MK, Deghmane AE, Antignac A, Zarantonelli ML, Larribe M, Alonso JM. The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol 2002; 10:376-82.
6. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129:1327-48.
7. Kremastinou J, Tzanakaki G, Pagalis A, Theodondou M, Weir DM, Blackwell CC. Detection of IgG and IgM to meningococcal outer membrane proteins in relation to carriage of Neisseria meningitidis or Neisseria lactamica. FEMS Immunol Med Microbiol 1999; 24:73-8.
8. Ala'Aldeen DA, Neal KR, Ait-Tahar K, Nguyen-Van-Tam JS, English A, Falla TJ, Hawkey PM, Slack RC. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J Clin Microbiol 2000; 38:2311-6.
9. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7.
10. Eckhardt M, Muhlenhoff M, Bethe A, Koopman J, Frosch M, Gerardy-Schahn R. Molecular characterization of eukaryoric polysialyltransferase-1. Nature 1995; 373:715-8.
11. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7.
12. Zimmer SM, Stephens DS. Meningococcal conjugate vaccines. Expert Opin Pharmacother 2004; 5:855-63.
13. Parent du Chatelet I, Traore Y, Gessner BD, Antignac A, Naccro B, Njanpop-Lafourcade BM, Ouedraogo MS, Tiendrebeogo SR, Varon E, Taha MK. Bacterial meningitis in Burkina Faso: Surveillance using field-based polymerase chain reaction testing. Clin Infect Dis 2005; 40:17-25.
14. Taha MK, Parent Du Chatelet I, Schlumberger M, Sanou I, Djibo S, de Chabalier F, Alonso JM. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002; 40:1083-4.
15. Traore Y, Njanpop-Lafourcade BM, Adjogble KL, Lourd M, Yaro S, Nacro B, Drabo A, Parent du Chatelet I, Mueller JE, Taha MK, Borrow R, Nicolas P, Alonso JM, Gessner BD. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006; 43:817-22.
16. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, Tenebray B, Kairo KK, Giorgini D, Chanteau S. Meningococcal meningitis: Unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-63.
17. Levy-Bruhl D, Perrocheau A, Mora M, Taha MK, Dromell-Chabrier S, Beytout J, Quatresous I. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dome (France). Euro Surveill 2002; 7:74-6.
18. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007; 31:101-7.
19. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829-31.
20. Lancellotti M, Guiiyoule A, Ruckly C, Hong E, Alonso JM, Taha MK. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 2006; 8:191-6.
21. Perez-Trallero E, Vicente D, Montes M, Cisterna R. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet 2002; 360:953.
22. Parkhill J, Achtman M, James KD, Bentley SD, Churcher C, Klee SR, Morelli G, Basham D, Brown D, Chillingworth T, Davies RM, Davis P, Devlin K, Feltwell T, Hamlin N, Holroyd S, Jagels K, Leather S, Moule S, Mungall K, Quail MA, Rajandream MA, Rutherford KM, Simmonds M, Skelton J, Whitehead S, Spratt BG, Barrell BG. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 2000; 404:502-6.
23. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, Ketchum KA, Hood DW, Peden JF, Dodson RJ, Nelson WC, Gwinn ML, DeBoy R, Peterson JD, Hickey EK, Haft DH, Salzberg SL, White O, Fleischmann RD, Dougherty BA, Mason T, Ciecko A, Parksey DS, Blair E, Cittone H, Clark EB, Cotton MD, Utterback TR, Khouri H, Qin H, Vamathevan J, Gill J, Scarlato V, Masignani V, Pizza M, Grandi G, Sun L, Smith HO, Fraser CM, Moxon ER, Rappuoli R, Venter JC. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287:1809-15.
24. Maiden MC. Population genetics of a transformable bacterium: The influence of horizontal genetic exchange on the biology of Neisseria meningitidis. FEMS Microbiol Lett 1993; 112:243-50.
25. Rokbi B, Mignon M, Caugant DA, Quentin-Millet MJ. Heterogeneity of tbpB, the transferrin-binding protein B gene, among serogroup B Neisseria meningitidis strains of the ET-5 complex. Clin Diagn Lab Immunol 1997; 4:522-9.
26. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MC. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 1996; 3:444-50.
27. Taha MK, Bichier E, Perrocheau A, Alonso JM. Circumvention of herd immunity during an outbreak of meningococcal disease could be correlated to escape mutation in the porA gene of Neisseria meningitidis. Infect Immun 2001; 69:1971-3.
28. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:10834-9.
29. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neissena meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191-6.
30. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-207, (discussion 8-10).
31. Holst J, Feiring B, Fuglesang JE, Hoiby EA, Nokleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neissena meningitidis serogroup B disease. Vaccine 2003; 21:734-7.
32. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm LO, Lindbak AK, Mogster B, Namork E, Rye U. Production, characterization and control of MenB-vaccine "Folkehelsa": An outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991; 14:67-79, (discussion -80).
33. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA 1999; 281:1520-7.
34. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, Jolley KA, Maiden MC, Heuberger S, Frosch M. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36.
35. Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Hoiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-5.
36. Taha MK, Zarantonelli ML, Alonso JM, Naess LM, Holst J, Feiring B, Rosenqvist E. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007; 25:2537-38.
37. Elias J, Harmsen D, Claus H, Hellenbrand W, Frosch M, Vogel U. Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis 2006; 12:1689-95.
38. Levy-Bruhl D. Is there a need for a public vaccine production capacity at European level? Euro Surveill 2006; 11.